8-K: Regulus Therapeutics Acquired by Novartis Subsidiary in $7.00 Cash Plus CVR Deal

Regulus Therapeutics Inc. has been acquired by Novartis AG's indirect wholly-owned subsidiary, Redwood Merger Sub Inc., for $7.00 per share in cash plus a contingent value right, following a successful tender offer.

Summary

• Regulus Therapeutics Inc. (the Company) has been acquired by Redwood Merger Sub Inc. (Merger Sub), an indirect wholly-owned subsidiary of Novartis AG (Parent).
• The acquisition price for each outstanding share of common stock was $7.00 in cash (the Closing Amount) plus one non-tradeable Contingent Value Right (CVR).
• Each CVR represents the right to receive an additional $7.00 in cash upon the first achievement of U.S. Regulatory Approval for the Product (farabursen/RGLS 8429) for the Indication (autosomal dominant polycystic kidney disease) by any Selling Entity prior to December 31, 2034.
• The tender offer, which commenced on May 27, 2025, expired as scheduled at 11:59 p.m., New York City time, on June 24, 2025, and was not extended.
• A total of 56,374,397 Shares (approximately 74.49% of outstanding shares) were validly tendered and not validly withdrawn, satisfying the Minimum Condition for the offer.
• Additionally, Notices of Guaranteed Delivery were delivered for 5,584,804 additional Shares, representing approximately 7.38% of outstanding shares.
• All conditions to the Offer were satisfied, and Merger Sub irrevocably accepted all validly tendered shares for payment.
• On June 25, 2025, the Merger was completed, with Regulus Therapeutics Inc. continuing as the surviving corporation and an indirect wholly-owned subsidiary of Parent.
• Outstanding shares not tendered (excluding those with appraisal rights) were automatically converted into the right to receive the Offer Price (cash plus CVR).
• Company stock options, restricted stock unit awards (RSU Awards, PSU Awards), warrants, and preferred stock were converted into cash and/or CVRs based on their exercise/conversion prices relative to the Closing Amount and the potential CVR value.

Sentiment

Score: 8

Explanation: The successful completion of the acquisition provides immediate cash value to shareholders and offers significant potential upside through the CVR, contingent on a key milestone. While the CVR is non-tradeable, the overall outcome is positive for Regulus shareholders, reflecting a successful exit for the company.

Positives

• The successful completion of the acquisition provides immediate cash value of $7.00 per share to Regulus Therapeutics Inc. shareholders.
• Shareholders also received a Contingent Value Right (CVR) per share, offering potential for an additional $7.00 in cash upon the achievement of a specific regulatory milestone, providing potential upside.
• The tender offer met the minimum condition with strong shareholder participation (approximately 74.49% of outstanding shares tendered), indicating broad acceptance of the acquisition terms.

Negatives

• Regulus Therapeutics Inc. will cease to be an independent publicly traded company, with its shares being delisted from Nasdaq and deregistered, removing liquidity for existing shareholders.
• The Contingent Value Rights (CVRs) are non-tradeable, meaning holders cannot sell them for cash prior to the milestone achievement, limiting liquidity and valuation flexibility.
• Company stock options with a per share exercise price equal to or greater than $14.00 were automatically canceled without any consideration.

Risks

• The Contingent Value Right (CVR) payment of $7.00 per CVR is entirely contingent on the achievement of U.S. Regulatory Approval for the Product (farabursen/RGLS 8429) for the Indication (autosomal dominant polycystic kidney disease) by December 31, 2034.
• There is no guarantee that the specified milestone will be achieved, and if it is not, CVR holders will receive no additional payment.
• The CVRs are non-tradeable, meaning holders cannot realize any value from them unless and until the milestone is achieved and the payment is made.
• While Parent is obligated to use 'Commercially Reasonable Efforts' to achieve the milestone, this term is subject to various scientific, technical, commercial, and regulatory factors, and does not guarantee success.
• Certain 'Disqualified Individuals' (a board member and officers) may incur excise taxes on compensation related to the merger, though the Company will pay or reimburse a portion, subject to a cap that may not apply if the CVR milestone is achieved.

Future Outlook

The future outlook for Regulus Therapeutics Inc. as an independent entity is terminated, as it is now an indirect wholly-owned subsidiary of Novartis AG. The primary forward-looking aspect relates to the Contingent Value Rights (CVRs), which offer holders a potential future payment of $7.00 per CVR if the Product (farabursen/RGLS 8429) achieves U.S. Regulatory Approval for autosomal dominant polycystic kidney disease by December 31, 2034. Parent is obligated to use 'Commercially Reasonable Efforts' to achieve this milestone.

Management Comments

• Merger Sub irrevocably accepted for payment all Shares validly tendered and not validly withdrawn pursuant to the Offer and will promptly pay for all Shares accepted pursuant to the Offer.
• Parent completed the acquisition of the Company by causing Merger Sub to merge with and into the Company... with the Company continuing as the surviving corporation... and as an indirect wholly owned subsidiary of Parent.
• Parent... shall... use Commercially Reasonable Efforts to achieve the Milestone.

Industry Context

This acquisition represents a common trend in the pharmaceutical and biotechnology industries where larger, established companies acquire smaller, innovative biotech firms to gain access to promising drug candidates and pipelines. Novartis's acquisition of Regulus, particularly for its microRNA-17 inhibiting compound farabursen (RGLS 8429) targeting autosomal dominant polycystic kidney disease, aligns with strategies to expand therapeutic portfolios and leverage specialized research. The inclusion of a Contingent Value Right (CVR) is also a frequent mechanism in biotech M&A, allowing the acquirer to mitigate risk by tying a portion of the purchase price to the successful achievement of clinical or regulatory milestones, while providing target shareholders with potential upside.

Comparison to Industry Standards

• The acquisition price of $7.00 cash plus a $7.00 CVR, totaling a potential $14.00 per share, is a specific valuation for Regulus Therapeutics Inc. based on its pipeline, particularly farabursen (RGLS 8429).
• The use of a non-tradeable CVR is a standard mechanism in biotech M&A, seen in deals like Sanofi's acquisition of Kadmon Holdings (up to $9.50 per share, including CVRs for a specific milestone) or Bristol Myers Squibb's acquisition of MyoKardia (no CVRs, but a high upfront premium). The structure here, with a 50/50 split between upfront cash and potential CVR, is a common risk-sharing approach.
• The 'Commercially Reasonable Efforts' clause for the CVR milestone is a standard legal provision in such agreements, aiming to ensure the acquirer continues development, though its interpretation can sometimes be a point of contention.

Management Changes

Corporate Governance

Related Party Transactions

• The Company entered into Excise Tax Agreements with a member of the Company Board, Stelios Papadopoulos, Ph.D., and certain officers, including Crispina Calsada, Joseph P. Hagan, and Preston S. Klassen, M.D. M.H.S. (each a 'Disqualified Individual').
• Under these agreements, if an excise tax under Section 4999 of the Internal Revenue Code is imposed on a Disqualified Individual due to compensation or benefits provided in connection with the Merger, the Company will pay or reimburse a portion of such excise tax plus any resulting taxes.
• These payments or reimbursements are subject to a cap, provided that if the CVR milestone is achieved, such cap will not apply to the tax gross-up payments with respect to payments pursuant to the CVR.

Stakeholder Impact

• Shareholders: Received $7.00 cash per share and one non-tradeable CVR per share, with potential for an additional $7.00 cash per CVR. They will lose liquidity as shares are delisted and deregistered.
• Employees (specifically Equity Award Holders): Company stock options, restricted stock units, and PSU awards were converted into cash and/or CVRs, providing a payout for their equity. Employee Equity Award Holders will receive CVR payments through the parent's payroll system, subject to withholding taxes.
• Management: Existing directors and executive officers were removed, and new directors/officers from the acquiring entity were appointed. Certain 'disqualified individuals' (board member and officers) are subject to excise tax agreements related to their merger compensation.
• Company (Regulus Therapeutics Inc.): Ceases to be an independent public entity and becomes an indirect wholly-owned subsidiary of Novartis AG, integrating into a larger pharmaceutical organization.

Next Steps

• Payment for validly tendered shares will be promptly made.
• Payment of cash and CVRs for non-tendered shares (excluding those with appraisal rights) will be processed.
• Payment of cash and/or CVRs for converted company stock options, restricted stock units, PSU awards, warrants, and preferred stock will occur.
• The Nasdaq Stock Market LLC is expected to file Form 25 with the SEC on June 25, 2025, to effect the delisting and deregistration of Regulus shares.
• The Company intends to file a Form 15 with the SEC to terminate registration of its shares and suspend reporting obligations.
• Potential future payment of $7.00 per CVR will be made if the U.S. Regulatory Approval milestone for farabursen for autosomal dominant polycystic kidney disease is achieved by December 31, 2034.

Key Dates

Keywords

Regulus Therapeutics, Novartis AG, Redwood Merger Sub Inc., Acquisition, Tender Offer, Merger, Contingent Value Right, CVR, Farabursen, RGLS 8429, Autosomal Dominant Polycystic Kidney Disease, ADPKD, Biotechnology, Pharmaceutical, Delisting, Deregistration, SEC 8-K, Corporate Governance, Management Change